Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab

Authors:

Abstract
Summary: Thrombotic microangiopathy (TMA) is a grave complication after haematopoietic stem cell transplantation (HSCT) and effective treatment is undefined. Five patients with postHSCT TMA, which was refractory to at least 1 week of plasma exchange and prednisolone, were treated with rituximab (375 mg/m2/week × 4). Remission was achieved in four patients, of whom three remained in remission and one had died of sepsis at a median follow‐up of 10 months. ADAMTS13 levels were low in all evaluable patients, and only one patient showed significant anti‐ADAMTS13 antibody. The levels of ADAMTS13 and anti‐ADAMTS13 antibody did not change significantly with rituximab‐induced remission.

This publication has 12 references indexed in Scilit: